Biblio
Export 472 results:
Author Title Type [ Year] Filters: First Letter Of Last Name is Y [Clear All Filters]
“Tau and Amyloid-β Pathology in Japanese Forensic Autopsy Series Under 40 Years of Age: Prevalence and Association with APOE Genotype and Suicide Risk.”, J Alzheimers Dis, vol. 72, no. 2, pp. 641-652, 2019.
, “An UNC5C Allele Predicts Cognitive Decline and Hippocampal Atrophy in Clinically Normal Older Adults.”, J Alzheimers Dis, vol. 68, no. 3, pp. 1161-1170, 2019.
, “Abnormal Functional Brain Networks in Mild Cognitive Impairment and Alzheimer's Disease: A Minimum Spanning Tree Analysis.”, J Alzheimers Dis, vol. 65, no. 4, pp. 1093-1107, 2018.
, “Abnormal Functional Brain Networks in Mild Cognitive Impairment and Alzheimer's Disease: A Minimum Spanning Tree Analysis.”, J Alzheimers Dis, vol. 65, no. 4, pp. 1093-1107, 2018.
, “Abnormalities of Resting State Cortical EEG Rhythms in Subjects with Mild Cognitive Impairment Due to Alzheimer's and Lewy Body Diseases.”, J Alzheimers Dis, vol. 62, no. 1, pp. 247-268, 2018.
, “Accuracy of Inferred APOE Genotypes for a Range of Genotyping Arrays and Imputation Reference Panels.”, J Alzheimers Dis, vol. 64, no. 1, pp. 49-54, 2018.
, “Alzheimer's Disease in Systemic Sclerosis Patients: A Nationwide Population-Based Cohort Study.”, J Alzheimers Dis, vol. 65, no. 1, pp. 117-124, 2018.
, “Amyloid-β25-35 Upregulates Endogenous Neuroprotectant Neuroglobin via NFκB Activation in vitro.”, J Alzheimers Dis, vol. 64, no. 4, pp. 1163-1174, 2018.
, “Amyloid-β25-35 Upregulates Endogenous Neuroprotectant Neuroglobin via NFκB Activation in vitro.”, J Alzheimers Dis, vol. 64, no. 4, pp. 1163-1174, 2018.
, “Amyloid-β25-35 Upregulates Endogenous Neuroprotectant Neuroglobin via NFκB Activation in vitro.”, J Alzheimers Dis, vol. 64, no. 4, pp. 1163-1174, 2018.
, “Amyloid-β25-35 Upregulates Endogenous Neuroprotectant Neuroglobin via NFκB Activation in vitro.”, J Alzheimers Dis, vol. 64, no. 4, pp. 1163-1174, 2018.
, “Analyses of Clinical Features and Investigations on Potential Mechanisms in Patients with Alzheimer's Disease and Olfactory Dysfunction.”, J Alzheimers Dis, vol. 66, no. 2, pp. 789-799, 2018.
, “Analyses of Clinical Features and Investigations on Potential Mechanisms in Patients with Alzheimer's Disease and Olfactory Dysfunction.”, J Alzheimers Dis, vol. 66, no. 2, pp. 789-799, 2018.
, “Analysis of Brain Donors' Demographic and Medical Characteristics to Facilitate the Construction of a Human Brain Bank in China.”, J Alzheimers Dis, vol. 66, no. 3, pp. 1245-1254, 2018.
, “Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1323-1332, 2018.
, “Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1323-1332, 2018.
, “The Association Between Body Mass Index, and Cognitive, Functional, and Behavioral Declines for Incident Dementia.”, J Alzheimers Dis, vol. 66, no. 4, pp. 1507-1517, 2018.
, “Association between Plasma Levels of PAI-1, tPA/PAI-1 Molar Ratio, and Mild Cognitive Impairment in Chinese Patients with Type 2 Diabetes Mellitus.”, J Alzheimers Dis, vol. 63, no. 2, pp. 835-845, 2018.
, “Association between α-Klotho and Deep White Matter Lesions in the Brain: A Pilot Case Control Study Using Brain MRI.”, J Alzheimers Dis, vol. 61, no. 1, pp. 145-155, 2018.
, “Association between α-Klotho and Deep White Matter Lesions in the Brain: A Pilot Case Control Study Using Brain MRI.”, J Alzheimers Dis, vol. 61, no. 1, pp. 145-155, 2018.
, “Associations of Angiotensin Converting Enzyme-1 and Angiotensin II Blood Levels and Cognitive Function.”, J Alzheimers Dis, vol. 63, no. 2, pp. 655-664, 2018.
, “Automated Multi-Atlas Segmentation of Hippocampal and Extrahippocampal Subregions in Alzheimer's Disease at 3T and 7T: What Atlas Composition Works Best?”, J Alzheimers Dis, vol. 63, no. 1, pp. 217-225, 2018.
, “Bone-Marrow-Derived Microglia-Like Cells Ameliorate Brain Amyloid Pathology and Cognitive Impairment in a Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 64, no. 2, pp. 563-585, 2018.
, “Ceftriaxone Improves Cognitive Function and Upregulates GLT-1-Related Glutamate-Glutamine Cycle in APP/PS1 Mice.”, J Alzheimers Dis, vol. 66, no. 4, pp. 1731-1743, 2018.
, “Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 581-588, 2018.
,